Key statistics
On Friday, Annovis Bio Inc (ANVS:NYQ) closed at 8.47, 86.98% above the 52 week low of 4.53 set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.59 |
---|---|
High | 8.82 |
Low | 8.45 |
Bid | 8.45 |
Offer | 9.06 |
Previous close | 8.64 |
Average volume | 165.05k |
---|---|
Shares outstanding | 13.05m |
Free float | 10.24m |
P/E (TTM) | -- |
Market cap | 110.57m USD |
EPS (TTM) | -4.42 USD |
Data delayed at least 15 minutes, as of Sep 21 2024 00:00 BST.
More ▼
- Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
- Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
- Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
- Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
- Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
- Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
More ▼